Wednesday, May 18, 2011

Surgery Viable for Advanced Prostate Cancer, Study Finds (HealthDay)

Surgery Viable for Advanced Prostate Cancer, Study Finds
(HealthDay)
:

"HealthDay - TUESDAY, May 17 (HealthDay News) --

Surgery to remove the prostate gland (radical prostatectomy) led to a 20-year survival rate for 80 percent of patients with advanced prostate cancer, a new study finds."

"We are doing a much better job of identifying and expanding candidates for surgery, which results in better, longer outcomes for so many of our patients," Dr. R. Jeffrey Karnes, of the department of urology, said in the news release.

Amgen's Xgeva delays prostate cancer bone pain (Reuters)

Amgen's Xgeva delays prostate cancer bone pain
(Reuters)
:

"Reuters - A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company believes will help boost the drug's market potential."

The drug is currently approved as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia as a treatment for osteoporosis.

PSA Test Could Be Improved to Spot Prostate Cancer (HealthDay)

PSA Test Could Be Improved to Spot Prostate Cancer
(HealthDay)
:

"HealthDay - MONDAY, May 16 (HealthDay News) --

Amid the controversy swirling around the value of PSA testing as a screen for prostate cancer, new evidence emerges that there may be ways to fine-tune the screening so it benefits more men, while avoiding unnecessary biopsies and treatment."

According to news conference moderator Dr. Christopher Amling, chief of urology at Oregon Health & Science University in Portland, the AUA modified its prostate cancer screening guidelines in 2009 to recommend that men should start screening at age 40, or age 45 at the latest.

New Drug Extends Life a Bit in Advanced Prostate Cancer (HealthDay)

New Drug Extends Life a Bit in Advanced Prostate Cancer
(HealthDay)
:

"HealthDay - MONDAY, May 16 (HealthDay News) --

For men with advanced hormone-resistant prostate cancer who have also failed chemotherapy, the new drug Zytiga (abiraterone acetate) along with the steroid prednisone appears to increase survival modestly, a new study reports."

Men taking the drug combination had an average survival of 14.8 months, compared with 10.9 months for men taking a placebo.

"This study tells us that there is a form of hormonal therapy, abiraterone, that works in people who had standard hormonal therapy and chemotherapy," said prostate cancer expert Dr. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital in Boston.

"It will provide people with late-stage disease with an opportunity for an extended survival that they didn't have before. I can't say it's a home run because it's only a few months improvement," he added.

Tuesday, May 17, 2011

Smoking Might Raise Odds for Prostate Cancer's Return (HealthDay)

Smoking Might Raise Odds for Prostate Cancer's Return
(HealthDay)
:

"HealthDay - MONDAY, May 16 (HealthDay News) --

In men who've had their prostate surgically removed due to prostate cancer, smoking seems linked to a rise in blood levels of prostate specific antigen (PSA) -- a measure
of the risk of cancer recurrence."

"These data indicate that smoking history could provide valuable insight and should be included in risk-assessment models for prostate cancer," study presenter Dr. Joseph C. Presti said in an AUA news release.

"The study also presents a strong message to men: quitting smoking now could impact your ability to survive prostate cancer later," he added.

Monday, May 16, 2011

Poor Sleep Tied to Incontinence, Impotence (HealthDay)

Poor Sleep Tied to Incontinence, Impotence
(HealthDay)
: "HealthDay - SATURDAY, May 14 (HealthDay News) -- Sleep problems are
associated with erectile dysfunction and urologic conditions such as
incontinence, according to the results of two new studies."

"We know that proper amounts of sleep and quality of sleep can impact a wide range of health conditions, including erectile function and lower urinary tract symptoms," AUA spokesman Dr. Kevin T. McVary said in an association news release. "These data may help us better assess how helping patients modify their sleep patterns may help improve their health and overall quality of life."

Because these studies were presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

Saturday, May 7, 2011

Surgery better for younger prostate patients: report (AFP)

Surgery better for younger prostate patients: report
(AFP)
: "

File picture shows a surgeon during an operation. Surgery appears to be a better treatment option for early prostate cancer than AFP - Surgery appears to be a better treatment option for early prostate cancer than 'watchful waiting,' particularly for younger patients, according to a Swedish study.


"